Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

Table 3 Multivariate analysis for pCR according to treatment groups

Platinum-containing chemotherapy (groups A1 + A2)
	HR	95% CI	P value	HR	95% CI	P value
Age	0.89	0.809–0.980	0.0066	0.88	0.797–0.973	0.0038
Dose	1.041	0.970–1.117	0.25	1.029	0.963–1.099	0.38
Treatment			0.32			0.19
A1	Reference			Reference
A2	0.39			0.29
Intratumoral CD4	1.009	0.996–1.022	*0.018*
Stromal CD4				1.002	1.000–1.004	*0.022*
Non-platinum-containing chemotherapy (groups B1 + B2)
	HR	95% CI	P value	HR	95% CI	P value
Age	1.02	0.893–1.169	0.75	1.009	0.883–1.153	0.89
Dose	1.091	0.975–1.222	0.022	1.096	0.968–1.241	0.029
Treatment			0.42			0.70
B1	Reference			Reference
B2	2.47			1.573
Intratumoral CD4	0.998	0.994–1.003	0.38
Stromal CD4				1.0003	0.998–1.002	0.73

A1 group taking paclitaxel + carboplatin, A2 group taking eribulin + carboplatin, B1 eribulin + cyclophosphamide, B2 eribulin + capecitabine, CI confidence interval, HR hazard ratio, Dose dose of paclitaxel in group A1, eribulin in groups A2, B1 and B2
Statistically significant P values are shown in italics

ISSN: 1741-7015